Long-acting GLP-1 receptor agonist. Glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, central satiety signaling.
Reference facts
- Also known as
- Ozempic, Wegovy, Rybelsus
- Category
- GLP-1 & Metabolic
- Mechanism of action
- Long-acting GLP-1 receptor agonist. Glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, central satiety signaling.
- Targets
- GLP-1R
- Indications under research or approved
- Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction (T2D + CVD)
- Regulatory status (reference entry)
- FDA-approved (Ozempic 2017, Rybelsus 2019, Wegovy 2021)
- Half-life
- ~165 hours (~7 days)
- Sequence
- HXEGTFTSDVSSYLEGQAAKEFIAWLVRGRG
- Sequence notes
- 31-residue GLP-1 analog. Aib at position 2 (X), C18 fatty diacid linker at Lys26, Arg substitution at position 34.
- Molecular weight (Da)
- 4114
- PDB accession
- 4ZGM
- Originator / sponsor
- Novo Nordisk
- First reported
- 2012
- Origin
- Developed by Novo Nordisk by extending the half-life of Liraglutide via a longer fatty diacid linker.
Primary References
- STEP-1 — Semaglutide for obesity, NEJM 2021
- SUSTAIN-6 — Cardiovascular outcomes, NEJM 2016
- FDA Wegovy label
Explore research articles about Semaglutide
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.